Hannu Tiri, Jari Jokelainen, Markku Timonen, Kaisa Tasanen, Laura Huilaja, Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents, Journal of the American Academy of Dermatology, Volume 79, Issue 3, 2018, Pages 514-519, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2018.02.067
Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents
|Author:||Tiri, Hannu1,2; Jokelainen, Jari3,4; Timonen, Markku4;|
1PEDEGO Research Unit, University of Oulu, Oulu, Finland
2Department of Dermatology and Medical Research Center Oulu Oulu, Finland
3Unit of General Practice, Oulu University Hospital, Oulu, Finland
4Center for Life Course Epidemiology and Systems Medicine, University of Oulu, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 0.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2018042518485
|Publish Date:|| 2019-03-05
Background: Hidradenitis suppurativa (HS) is associated with various somatic and psychiatric comorbidities. Data regarding comorbidities in young patients with HS are sparse.
Objective: We analyzed both somatic and psychiatric comorbidities in young patients in a nationwide HS cohort.
Methods: In this retrospective case-control study, data from cases of HS in young (age 5 to <18 years) patients and age-matched controls with benign melanocytic nevi were collected from the Finnish Care Register for Health Care. The prevalence of preselected comorbidities was compared between the HS and control groups.
Results: A total of 153 HS cases were found in the specified age group. Of these, 34.0% had at least 1 somatic comorbidity compared with 4.9% of the controls. At least 1 of the preselected psychiatric diagnoses was present before the age of 18 years in 15.7% of case patients with HS compared with in 5.6% of the controls. By the age of 23 years, 23.5% of the patients with HS and 8.7% of the controls had at least 1 identified psychiatric comorbidity.
Limitations: Despite this being one of the largest HS cohorts ever studied, the number of young patients with HS was relatively low. Because this was a registry-based study, it was not possible to verify the accuracy of the International Classification of Diseases codes.
Conclusions: Physicians should monitor young patients with HS for both somatic and psychiatric comorbidities.
Journal of the American Academy of Dermatology
|Pages:||514 - 519|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
© 2018 by the American Academy of Dermatology, Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/